ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 117 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,867,804 | -22.5% | 442,064 | +8.9% | 0.00% | 0.0% |
| Q2 2023 | $11,448,887 | +99.5% | 405,845 | +21.7% | 0.00% | +50.0% |
| Q1 2023 | $5,737,370 | -15.2% | 333,568 | -0.7% | 0.00% | 0.0% |
| Q4 2022 | $6,762,146 | -3.5% | 335,757 | +3.8% | 0.00% | -33.3% |
| Q3 2022 | $7,008,000 | -22.2% | 323,503 | +0.9% | 0.00% | 0.0% |
| Q2 2022 | $9,008,000 | -27.1% | 320,543 | +19.7% | 0.00% | -25.0% |
| Q1 2022 | $12,358,000 | -43.7% | 267,837 | +2.6% | 0.00% | -33.3% |
| Q4 2021 | $21,941,000 | +30.4% | 261,006 | +3.3% | 0.01% | 0.0% |
| Q3 2021 | $16,830,000 | +105.1% | 252,550 | +63.7% | 0.01% | +100.0% |
| Q2 2021 | $8,207,000 | +46.8% | 154,264 | +19.7% | 0.00% | +50.0% |
| Q1 2021 | $5,591,000 | -13.5% | 128,845 | +3.5% | 0.00% | -33.3% |
| Q4 2020 | $6,466,000 | +128.2% | 124,488 | +43.6% | 0.00% | +200.0% |
| Q3 2020 | $2,834,000 | -10.3% | 86,671 | +31.7% | 0.00% | -50.0% |
| Q2 2020 | $3,160,000 | – | 65,805 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |